These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 7628197)

  • 1. Influence of beta-lactamase inhibitors on the activity of oxacillin against methicillin-resistant Staphylococcus aureus.
    Chang SC; Hsieh WC; Luh KT
    Diagn Microbiol Infect Dis; 1995 Feb; 21(2):81-4. PubMed ID: 7628197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antistaphylococcal activity of amoxicillin and ticarcillin when combined with clavulanic acid. Evaluation of oxacillin-resistant and oxacillin-susceptible isolates.
    Barry AL
    Diagn Microbiol Infect Dis; 1990; 13(5):357-61. PubMed ID: 2282775
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of beta-lactamase in staphylococcal resistance to penicillinase-resistant penicillins and cephalosporins.
    McDougal LK; Thornsberry C
    J Clin Microbiol; 1986 May; 23(5):832-9. PubMed ID: 3011847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro effects of beta-lactams combined with beta-lactamase inhibitors against methicillin-resistant Staphylococcus aureus.
    Kobayashi S; Arai S; Hayashi S; Sakaguchi T
    Antimicrob Agents Chemother; 1989 Mar; 33(3):331-5. PubMed ID: 2786369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diversity of methicillin-resistant Staphylococcus aureus isolated in a Canadian hospital.
    Hammerberg O; Bialkowska-Hobrzanska H; Gregson D; McGhie K; Behme R
    Eur J Clin Microbiol Infect Dis; 1995 Mar; 14(3):199-205. PubMed ID: 7614960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of beta-lactamase and different testing conditions in oxacillin-borderline-susceptible staphylococci.
    Sierra-Madero JG; Knapp C; Karaffa C; Washington JA
    Antimicrob Agents Chemother; 1988 Dec; 32(12):1754-7. PubMed ID: 3266728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam.
    Kuck NA; Jacobus NV; Petersen PJ; Weiss WJ; Testa RT
    Antimicrob Agents Chemother; 1989 Nov; 33(11):1964-9. PubMed ID: 2558615
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of vancomycin in combination with piperacillin-tazobactam or oxacillin against clinical methicillin-resistant Staphylococcus aureus Isolates and vancomycin-intermediate S. aureus isolates in vitro.
    Dilworth TJ; Sliwinski J; Ryan K; Dodd M; Mercier RC
    Antimicrob Agents Chemother; 2014; 58(2):1028-33. PubMed ID: 24277036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains.
    Higgins PG; Wisplinghoff H; Stefanik D; Seifert H
    Antimicrob Agents Chemother; 2004 May; 48(5):1586-92. PubMed ID: 15105109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro evaluation of the four beta-lactamase inhibitors: BRL42715, clavulanic acid, sulbactam, and tazobactam.
    Muratani T; Yokota E; Nakane T; Inoue E; Mitsuhashi S
    J Antimicrob Chemother; 1993 Sep; 32(3):421-9. PubMed ID: 8262864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative efficacy of tazobactam, sulbactam and clavulanic acid in enhancing the potency of ampicillin against clinical isolates of Enterobacteriaceae.
    Pfaller M; Barry A; Fuchs P; Gerlach E; Hardy D; McLaughlin J
    Eur J Clin Microbiol Infect Dis; 1993 Mar; 12(3):200-5. PubMed ID: 8389705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of cefpirome combined with beta-lactamase inhibitors and affinity for the penicillin-binding proteins of methicillin-resistant Staphylococcus aureus.
    Piddock LJ; Traynor EA; Griggs DJ
    Eur J Clin Microbiol Infect Dis; 1992 Apr; 11(4):364-71. PubMed ID: 1396760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of borderline oxacillin-resistant Staphylococcus aureus and differentiation from methicillin-resistant strains.
    Liu H; Buescher G; Lewis N; Snyder S; Jungkind D
    Eur J Clin Microbiol Infect Dis; 1990 Oct; 9(10):717-24. PubMed ID: 2261916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS; Tosin I; Sejas L; Miranda E
    Braz J Infect Dis; 2000 Feb; 4(1):22-8. PubMed ID: 10788842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tazobactam-piperacillin compared with sulbactam-ampicillin, clavulanic acid-ticarcillin, sulbactam-cefoperazone, and piperacillin for activity against beta-lactamase-producing bacteria isolated from patients with complicated urinary tract infections.
    Nomura S; Hanaki H; Nagayama A
    J Chemother; 1997 Apr; 9(2):89-94. PubMed ID: 9176745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-vitro activity of penicillin G plus sulbactam in comparison with other beta-lactamase inhibitor combinations and oxacillin against staphylococci.
    Jansen B; Perdreau-Remington F; Pulverer G
    Zentralbl Bakteriol; 1996 Jul; 284(2-3):297-301. PubMed ID: 8837390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro activity of combinations of beta-lactam antibiotics with beta-lactamase inhibitors against cephalosporinase-producing bacteria.
    Kitzis MD; Ferré B; Coutrot A; Acar JF; Gutmann L
    Eur J Clin Microbiol Infect Dis; 1989 Sep; 8(9):783-8. PubMed ID: 2556277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Susceptibilities of beta-lactamase-positive and -negative strains of Campylobacter coli to beta-lactam agents.
    Lachance N; Gaudreau C; Lamothe F; Turgeon F
    Antimicrob Agents Chemother; 1993 May; 37(5):1174-6. PubMed ID: 8390812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vancomycin and piperacillin-tazobactam against methicillin-resistant Staphylococcus aureus and vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.
    Dilworth TJ; Leonard SN; Vilay AM; Mercier RC
    Clin Ther; 2014 Oct; 36(10):1334-44. PubMed ID: 25066667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibility of clinical isolates to expanded-spectrum beta-lactams alone and in the presence of beta-lactamase inhibitors.
    Qadri SM; Ueno Y; Cunha BA
    Chemotherapy; 1996; 42(5):334-42. PubMed ID: 8874972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.